2266 - Hypofractionated Radiotherapy Combined with Nal-IRI + 5-FU/LV, Enlonstobart and Target Therapy in Locally Recurrent Rectal Cancer (NOVELTY-R): A Single-Arm Open-Label, Phase II Trial

03:00pm - 04:00pm ET

Presenter(s)

Ruiyan Wu, MD, PhD - Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai,